TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
Go back to TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.71 +3.13 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $196.58 | 52 Week High | $333.65 | |||
| Open | $199.48 | 52 Week Low | $223.02 | |||
| Day High | $200.98 | P/E | 25.57 | |||
| Day Low | $194.74 | EPS | $7.81 | |||
| Volume | 1,675,269 | |||||
